Page data last changed: . Registry refreshes and identity assessments are separate from scientific content review.
Engineered to mimic the complementary effects of GLP-1 and glucagon without dose titration in reported protocols.
Also known as: ALT-801
Part of the Metabolic & GLP-1 peptides cluster
Overview
Pemvidutide (ALT-801) is an investigational dual GLP-1/glucagon receptor agonist developed by Altimmune and studied in clinical trials for obesity and MASH. It illustrates how a lipidated peptide can be designed for once-weekly dosing. It is not authorized by Health Canada, and this page is educational only.
Source & context
Biological / chemical source: Synthetic peptide with a lipid moiety engineered for weekly subcutaneous dosing
Primary research or clinical context: Investigational compound (Altimmune); studied in trials for obesity and metabolic dysfunction-associated steatohepatitis — not authorized by Health Canada
Design and dosing
Pemvidutide is a lipidated peptide that activates both the GLP-1 and glucagon receptors. In the developer's framework, GLP-1 activity supports appetite and glucose signalling while glucagon activity is associated with energy expenditure and hepatic lipid handling. The lipid moiety extends its half-life to support once-weekly subcutaneous administration in reported trials.
Research and regulatory status
Pemvidutide has been evaluated in phase 2 obesity and liver trials. It remains investigational and is not authorized by Health Canada. This educational summary describes its mechanism and development history without asserting any therapeutic benefit; decisions about metabolic health belong with a licensed clinician.
Structure & chemistry
Molecular identity & reference confidence
Reference mass unavailable
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Pemvidutide (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
Clinical development snapshot
ClinicalTrials.gov lists 8 registered studies with “Pemvidutide” as an intervention (snapshot 2026-10-01). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT07795164 | Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH | Phase 3 | recruiting | 2026-09-23 |
| NCT07009860 | RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Di | Phase 2 | active not recruiting | 2026-08-17 |
| NCT06987513 | RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorde | Phase 2 | completed | 2026-07-31 |
| NCT05989711 | IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) | Phase 2 | completed | 2026-05-18 |
| NCT04972396 | Pemvidutide (ALT-801) DDI Study in Healthy Volunteers | Phase 1 | completed | 2025-06-24 |
| NCT04561245 | ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability | Phase 1 | completed | 2025-06-24 |
FAQ about Pemvidutide
What is Pemvidutide?+
Pemvidutide (ALT-801) is an investigational dual GLP-1/glucagon receptor agonist developed by Altimmune and studied in clinical trials for obesity and MASH. It illustrates how a lipidated peptide can be designed for once-weekly dosing. It is not authorized by Health Canada, and this page is educational only.
What Canadian product status is recorded for Pemvidutide?+
Canadian product status for Pemvidutide has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Pemvidutide?+
Pemvidutide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.
Related peptides
References & further reading
- 1.Harrison et al. (2025). Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol
- 2.Noureddin et al. (2025). Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet
- 3.Tacke (2025). The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial. Lancet
- 4.Browne et al. (2025). Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP Rep
- 5.Rajab et al. (2026). Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol
- 6.Nestor et al. (2022). Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. Sci Rep
- 7.Fishman et al. (2011). Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res
- 8.Altimmune — Pemvidutide program page
- 9.Wikipedia — Pemvidutide